2022 annual financial data
Lyell Immunopharma 2022 Net margin
Direct answer
Net margin was -216.24%.
Operating income was -187,058,000 USD and net income was -183,118,000 USD.
Operating cash flow was -169,555,000 USD.
Get free Lyell Immunopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 84,683,000 USD
- Operating income
- -187,058,000 USD
- Net income
- -183,118,000 USD
- Operating cash flow
- -169,555,000 USD